Clinical Trial Update: MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. [Phase 1, Phase 2]

View source ↗

Summary

Pfizer's MEK inhibitor PD-325901 was tested in Phase 1/2 trials for advanced breast cancer, colorectal cancer, and melanoma, but the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Melanoma

Drugs mentioned

• PD-325901

Snippet

Sponsor: Pfizer | Conditions: Melanoma, Colonic Neoplasms | Phase 1, Phase 2 | Status: TERMINATED